CRMD
CorMedix Inc.
$7.98
-0.08
(-0.99%)
Mkt Cap
626.05M
Volume
773,330
52W Range
6.13-17.43
Sector
Healthcare
Beta
1.46
EPS (TTM)
2.38
P/E Ratio
3.35
Revenue (TTM)
400.05M
Rev Growth (5Y)
+319.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$71.88
Undervalued · Strong
88.9% below fair value
AlphaQuality · Grade · Gated
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
Company Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 311.71M | 43.47M | 0 | 65,408 | 190,936 | 239,231 | 283,266 | 429,797 | 329,327 | 224,105 | 210,130 | 189,274 |
| Net Income | 163.06M | (17.93M) | (46.34M) | (29.70M) | (28.21M) | (22.03M) | (16.43M) | (26.83M) | (33.01M) | (24.64M) | (18.19M) | (20.45M) |
| EPS | 2.25 | -0.30 | -0.91 | -0.74 | -0.75 | -0.77 | -0.68 | -1.51 | -2.99 | -3.25 | -2.90 | -4.77 |
| Free Cash Flow | 172.79M | (50.73M) | (38.74M) | (24.58M) | (22.58M) | (22.08M) | (15.09M) | (23.75M) | (28.74M) | (22.32M) | N/A | N/A |
| FCF / Share | 2.40 | -0.86 | -0.76 | -0.61 | -0.60 | -0.77 | -0.62 | -1.33 | -2.61 | -2.94 | N/A | N/A |
| Operating CF | 175.05M | (50.61M) | (38.41M) | (24.36M) | (21.16M) | (21.97M) | (15.05M) | (23.70M) | (28.59M) | (22.27M) | N/A | N/A |
| Total Assets | 826.14M | 118.85M | 82.06M | 62.04M | 68.95M | 49.31M | 29.48M | 18.83M | 13.45M | 21.91M | N/A | N/A |
| Total Debt | 148.91M | 517,013 | 667,632 | 802,433 | 923,801 | 1.03M | 4,689 | 6.13M | 0 | 0 | N/A | N/A |
| Cash & Equiv | 145.82M | 40.65M | 43.64M | 43.37M | 53.32M | 41.91M | 16.53M | 17.62M | 10.38M | 8.06M | N/A | N/A |
| Book Value | 405.31M | 84.66M | 70.14M | 55.06M | 62.80M | 44.22M | (195.42M) | (178.99M) | (152.17M) | 17.81M | N/A | N/A |
| Return on Equity | 0.40 | -0.21 | -0.66 | -0.54 | -0.45 | -0.50 | N/A | N/A | N/A | -1.38 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.43M | 128.62M | 104.28M | 39.74M | 39.08M | 31.21M | 11.46M | 806,119 | 0 | 0 | 0 | 0 |
| Net Income | 38.60M | 14.02M | 108.56M | 19.83M | 20.64M | 13.46M | (2.78M) | (14.15M) | (14.47M) | (14.75M) | (9.74M) | (11.27M) |
| EPS | 0.49 | 0.18 | 1.42 | 0.29 | 0.32 | 0.22 | -0.05 | -0.25 | -0.25 | -0.26 | -0.17 | -0.25 |
| Free Cash Flow | 41.65M | 94.42M | 30.35M | 29.97M | 19.73M | (5.62M) | (13.66M) | (14.07M) | (17.37M) | (11.04M) | (8.71M) | (8.58M) |
| FCF / Share | 0.52 | 1.20 | 0.40 | 0.44 | 0.30 | -0.09 | -0.23 | -0.24 | -0.30 | -0.19 | -0.15 | -0.19 |
| Operating CF | 42.38M | 94.46M | 30.86M | 29.99M | 19.74M | (5.61M) | (13.65M) | (14.04M) | (17.31M) | (10.75M) | (8.70M) | (8.57M) |
| Total Assets | 815.64M | 826.14M | 750.86M | 252.60M | 149.58M | 118.85M | 77.59M | 57.73M | 68.02M | 82.06M | 91.43M | 57.03M |
| Total Debt | 144.88M | 148.91M | 148.92M | 435,245 | 476,587 | 517,013 | 556,416 | 594,323 | 631,389 | 667,632 | 702,947 | 736,855 |
| Cash & Equiv | 178.09M | 145.82M | 48.49M | 159.31M | 66.29M | 40.65M | 35.29M | 28.54M | 35.18M | 43.64M | 53.31M | 19.79M |
| Book Value | 437.05M | 405.31M | 374.13M | 220.63M | 114.89M | 84.66M | 58.71M | 46.18M | 58.01M | 70.14M | 83.20M | 49.05M |
| Return on Equity | 0.09 | 0.03 | 0.29 | 0.09 | 0.18 | 0.16 | -0.05 | -0.31 | -0.25 | -0.21 | -0.12 | -0.23 |
CRMD News
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026